Literature DB >> 22846158

Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma.

Fabian V Filipp1, Boris Ratnikov, Jessica De Ingeniis, Jeffrey W Smith, Andrei L Osterman, David A Scott.   

Abstract

In this perspective, we revise the historic notion that cancer is a disease of mitochondria. We summarize recent findings on the function and rewiring of central carbon metabolism in melanoma. Metabolic profiling studies using stable isotope tracers show that glycolysis is decoupled from the tricarboxylic acid (TCA) cycle. This decoupling is not 'dysfunction' but rather an alternate wiring required by tumor cells to remain metabolically versatile. In large part, this requirement is met by glutamine feeding the TCA cycle as an alternative source of carbon. Glutamine is also used in non-conventional ways, like traveling in reverse through the TCA flux to feed fatty acid biosynthesis. Biosynthetic networks linked with non-essential amino acids alanine, serine, arginine, and proline are also significantly impacted by the use of glutamine as an alternate carbon source.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22846158      PMCID: PMC3639292          DOI: 10.1111/pcmr.12000

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  42 in total

1.  Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction.

Authors:  David R Wise; Ralph J DeBerardinis; Anthony Mancuso; Nabil Sayed; Xiao-Yong Zhang; Harla K Pfeiffer; Ilana Nissim; Evgueni Daikhin; Marc Yudkoff; Steven B McMahon; Craig B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-24       Impact factor: 11.205

2.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.

Authors:  Katherine A Janeway; Su Young Kim; Maya Lodish; Vânia Nosé; Pierre Rustin; José Gaal; Patricia L M Dahia; Bernadette Liegl; Evan R Ball; Margarita Raygada; Angela H Lai; Lorna Kelly; Jason L Hornick; Maureen O'Sullivan; Ronald R de Krijger; Winand N M Dinjens; George D Demetri; Cristina R Antonescu; Jonathan A Fletcher; Lee Helman; Constantine A Stratakis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

Review 3.  Cancer morphogenesis: role of mitochondrial failure.

Authors:  Egil Fosslien
Journal:  Ann Clin Lab Sci       Date:  2008       Impact factor: 1.256

4.  c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism.

Authors:  Ping Gao; Irina Tchernyshyov; Tsung-Cheng Chang; Yun-Sil Lee; Kayoko Kita; Takafumi Ochi; Karen I Zeller; Angelo M De Marzo; Jennifer E Van Eyk; Joshua T Mendell; Chi V Dang
Journal:  Nature       Date:  2009-02-15       Impact factor: 49.962

5.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

6.  Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling.

Authors:  Chendong Yang; Jessica Sudderth; Tuyen Dang; Robert M Bachoo; Robert G Bachoo; Jeffrey G McDonald; Ralph J DeBerardinis
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

Review 7.  Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.

Authors:  Barbara Delage; Dean A Fennell; Linda Nicholson; Iain McNeish; Nicholas R Lemoine; Tim Crook; Peter W Szlosarek
Journal:  Int J Cancer       Date:  2010-06-15       Impact factor: 7.396

8.  Quiescent fibroblasts exhibit high metabolic activity.

Authors:  Johanna M S Lemons; Xiao-Jiang Feng; Bryson D Bennett; Aster Legesse-Miller; Elizabeth L Johnson; Irene Raitman; Elizabeth A Pollina; Herschel A Rabitz; Joshua D Rabinowitz; Hilary A Coller
Journal:  PLoS Biol       Date:  2010-10-19       Impact factor: 8.029

9.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

10.  IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain.

Authors:  Giselle Y Lopez; Zachary J Reitman; David Solomon; Todd Waldman; Darell D Bigner; Roger E McLendon; Steven A Rosenberg; Yardena Samuels; Hai Yan
Journal:  Biochem Biophys Res Commun       Date:  2010-07-13       Impact factor: 3.322

View more
  49 in total

1.  Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies.

Authors:  Young Joo Jeon; Sihem Khelifa; Boris Ratnikov; David A Scott; Yongmei Feng; Fabio Parisi; Chelsea Ruller; Eric Lau; Hyungsoo Kim; Laurence M Brill; Tingting Jiang; David L Rimm; Robert D Cardiff; Gordon B Mills; Jeffrey W Smith; Andrei L Osterman; Yuval Kluger; Ze'ev A Ronai
Journal:  Cancer Cell       Date:  2015-03-09       Impact factor: 31.743

Review 2.  Glucose and glutamine metabolism control by APC and SCF during the G1-to-S phase transition of the cell cycle.

Authors:  Irving Omar Estévez-García; Verónica Cordoba-Gonzalez; Eleazar Lara-Padilla; Abel Fuentes-Toledo; Ramcés Falfán-Valencia; Rafael Campos-Rodríguez; Edgar Abarca-Rojano
Journal:  J Physiol Biochem       Date:  2014-03-07       Impact factor: 4.158

Review 3.  Updates of reactive oxygen species in melanoma etiology and progression.

Authors:  Feng Liu-Smith; Ryan Dellinger; Frank L Meyskens
Journal:  Arch Biochem Biophys       Date:  2014-04-26       Impact factor: 4.013

Review 4.  Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.

Authors:  Kristin G Anderson; Ingunn M Stromnes; Philip D Greenberg
Journal:  Cancer Cell       Date:  2017-03-13       Impact factor: 31.743

5.  1H NMR Metabolomics Study of Metastatic Melanoma in C57BL/6J Mouse Spleen.

Authors:  Xuan Wang; Mary Hu; Ju Feng; Maili Liu; Jian Zhi Hu
Journal:  Metabolomics       Date:  2014-12       Impact factor: 4.290

6.  Pulmonary artery smooth muscle cell hyperproliferation and metabolic shift triggered by pulmonary overcirculation.

Authors:  Jason Boehme; Xutong Sun; Kathryn V Tormos; Wenhui Gong; Manuela Kellner; Sanjeev A Datar; Rebecca Johnson Kameny; Jason X-J Yuan; Gary W Raff; Jeffrey R Fineman; Stephen M Black; Emin Maltepe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-09-02       Impact factor: 4.733

Review 7.  Metabotropic glutamate receptors in cancer.

Authors:  Lumeng J Yu; Brian A Wall; Janet Wangari-Talbot; Suzie Chen
Journal:  Neuropharmacology       Date:  2016-02-16       Impact factor: 5.250

Review 8.  Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications.

Authors:  Grant M Fischer; Y N Vashisht Gopal; Jennifer L McQuade; Weiyi Peng; Ralph J DeBerardinis; Michael A Davies
Journal:  Pigment Cell Melanoma Res       Date:  2017-11-02       Impact factor: 4.693

Review 9.  Metabolic advantages and vulnerabilities in brain metastases.

Authors:  Alexandra K Ciminera; Rahul Jandial; John Termini
Journal:  Clin Exp Metastasis       Date:  2017-10-23       Impact factor: 5.150

Review 10.  Cancer metabolism: a therapeutic perspective.

Authors:  Ubaldo E Martinez-Outschoorn; Maria Peiris-Pagés; Richard G Pestell; Federica Sotgia; Michael P Lisanti
Journal:  Nat Rev Clin Oncol       Date:  2016-05-04       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.